Spyre Therapeutics (SYRE) Insider Thomas Sells $2M of Stock

Henderson Michael Thomas, an insider at Spyre Therapeutics, Inc. (NasdaqGS: SYRE), sold 20,000 shares of the company on June 22, 2026. The shares were sold at an average price of $100 each, making the total transaction worth $2 million. This sale was planned, as indicated by the insider trading report.

Insider Buying and Selling at Spyre Therapeutics, Inc.

In addition to Henderson's sale, Fairmount Funds Management LLC was active on June 23, selling 4,684,781 shares and buying 666,680 shares in different transactions. Chief Medical Officer Sheldon Sloan also sold 8,333 shares on June 3, with a planned sale at $75 per share.

Other Institutional Activity in Spyre Therapeutics

FMR LLC increased its holdings in Spyre by 142,205 shares, bringing its total to over 11.78 million shares valued at approximately $594.23 million. Perceptive Advisors LLC also boosted its position by 714,000 shares, totaling 3.78 million shares worth around $190.83 million, marking a 23.3% increase. Meanwhile, BlackRock, Inc. slightly reduced its stake by 880 shares, maintaining over 5.52 million shares valued at $278.49 million.

Spyre Therapeutics, Inc. Stock Up 7.5%

On Wednesday, shares of Spyre Therapeutics traded near $100.32. The company, which has a market cap of $8.71 billion, operates in the biotechnology sector. Despite not being profitable, it has a forward P/E ratio of -32.17 and a beta of 3.063. The stock's 52-week range is between $14.00 and $101.71, with a 50-day moving average of $72.73 and a 200-day moving average of $40.89.

Analysts Set New Price Targets

Analysts are optimistic about Spyre Therapeutics, with Deutsche Bank maintaining a 'buy' rating and setting a price target of $135 on June 23. BTIG also kept its 'buy' rating with a target of $112 on June 16. The consensus among analysts is a strong buy, with a mean target price of $99.13 across 15 opinions.

About Spyre Therapeutics

Spyre Therapeutics, Inc., based in Waltham, Massachusetts, is a clinical-stage biotech company focused on developing treatments for inflammatory bowel disease and rheumatic diseases. Led by CEO Dr. Cameron Turtle, the company is working on several innovative therapies, including SPY001, SPY002, and SPY072, which target specific proteins involved in these conditions. Spyre aims to address unmet medical needs in these challenging disease areas.

Bottom Line

The insider sale by Henderson Michael Thomas at Spyre Therapeutics is part of a planned transaction, reflecting routine insider activity. Investors often watch such transactions for insights into company insiders' perspectives. With a strong buy consensus from analysts and significant institutional activity, Spyre remains a closely watched player in the biotech sector.